High-dose administration of levofloxacin (LVFX) in the treatment of acute exacerbation of chronic otitis media

Kazunori Nishizaki; Hirofumi Akagi; Kunihiro Fukushima; Yu Masuda; Manabu Maeta; Yasushi Takeda; Toshiaki Ogawara; Shin Kariya; Seiko Akagi; Hiroyuki Teshima; Kaori Shirakami

doi:10.5631/jibirin.93.77

High-dose administration of levofloxacin (LVFX) in the treatment of acute exacerbation of chronic otitis media

Kazunori Nishizaki, Hirofumi Akagi, Kunihiro Fukushima, Yu Masuda, Manabu Maeta, Yasushi Takeda, Toshiaki Ogawara, Shin Kariya, Seiko Akagi, Hiroyuki Teshima, Kaori Shirakami

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Thirty-two adult cases of acute exacerbation of chronic otitis media (COM) were treated by high-dose (600 mg/day) oral administration of levofloxacin (LVFX). Clinically, 27 COM cases (84.4%) were effectively treated, and no apparent side effects were noted during this study protocol. Among 31 clinically isolated strains whose therapeutic outcomes were bacteriologically confirmed, 28(90%) strains were not detectable after high- dose LVFX treatment. Bacteriological therapeutic failures in the treatment were observed in three COM patients with MRSA and a patient with coagulase- negative staphylococci. High-dose administration of LVFX was effective in the treatment of acute exacerbation of COM except in cases that were caused by drug resistant staphylococci.

Original language	English
Pages (from-to)	77-84
Number of pages	8
Journal	Practica Otologica
Volume	93
Issue number	1
DOIs	https://doi.org/10.5631/jibirin.93.77
Publication status	Published - 2000
Externally published	Yes

Keywords

Chronic otitis media
Levofloxacin (LVFX)
MRSA

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.5631/jibirin.93.77

Cite this

@article{6922cf4417c34ca2b1f4a188e42bc7c3,

title = "High-dose administration of levofloxacin (LVFX) in the treatment of acute exacerbation of chronic otitis media",

abstract = "Thirty-two adult cases of acute exacerbation of chronic otitis media (COM) were treated by high-dose (600 mg/day) oral administration of levofloxacin (LVFX). Clinically, 27 COM cases (84.4%) were effectively treated, and no apparent side effects were noted during this study protocol. Among 31 clinically isolated strains whose therapeutic outcomes were bacteriologically confirmed, 28(90%) strains were not detectable after high- dose LVFX treatment. Bacteriological therapeutic failures in the treatment were observed in three COM patients with MRSA and a patient with coagulase- negative staphylococci. High-dose administration of LVFX was effective in the treatment of acute exacerbation of COM except in cases that were caused by drug resistant staphylococci.",

keywords = "Chronic otitis media, Levofloxacin (LVFX), MRSA",

author = "Kazunori Nishizaki and Hirofumi Akagi and Kunihiro Fukushima and Yu Masuda and Manabu Maeta and Yasushi Takeda and Toshiaki Ogawara and Shin Kariya and Seiko Akagi and Hiroyuki Teshima and Kaori Shirakami",

year = "2000",

doi = "10.5631/jibirin.93.77",

language = "English",

volume = "93",

pages = "77--84",

journal = "Practica Otologica",

issn = "0032-6313",

publisher = "Society of Practical Otolaryngology",

number = "1",

}

TY - JOUR

T1 - High-dose administration of levofloxacin (LVFX) in the treatment of acute exacerbation of chronic otitis media

AU - Nishizaki, Kazunori

AU - Akagi, Hirofumi

AU - Fukushima, Kunihiro

AU - Masuda, Yu

AU - Maeta, Manabu

AU - Takeda, Yasushi

AU - Ogawara, Toshiaki

AU - Kariya, Shin

AU - Akagi, Seiko

AU - Teshima, Hiroyuki

AU - Shirakami, Kaori

PY - 2000

Y1 - 2000

N2 - Thirty-two adult cases of acute exacerbation of chronic otitis media (COM) were treated by high-dose (600 mg/day) oral administration of levofloxacin (LVFX). Clinically, 27 COM cases (84.4%) were effectively treated, and no apparent side effects were noted during this study protocol. Among 31 clinically isolated strains whose therapeutic outcomes were bacteriologically confirmed, 28(90%) strains were not detectable after high- dose LVFX treatment. Bacteriological therapeutic failures in the treatment were observed in three COM patients with MRSA and a patient with coagulase- negative staphylococci. High-dose administration of LVFX was effective in the treatment of acute exacerbation of COM except in cases that were caused by drug resistant staphylococci.

AB - Thirty-two adult cases of acute exacerbation of chronic otitis media (COM) were treated by high-dose (600 mg/day) oral administration of levofloxacin (LVFX). Clinically, 27 COM cases (84.4%) were effectively treated, and no apparent side effects were noted during this study protocol. Among 31 clinically isolated strains whose therapeutic outcomes were bacteriologically confirmed, 28(90%) strains were not detectable after high- dose LVFX treatment. Bacteriological therapeutic failures in the treatment were observed in three COM patients with MRSA and a patient with coagulase- negative staphylococci. High-dose administration of LVFX was effective in the treatment of acute exacerbation of COM except in cases that were caused by drug resistant staphylococci.

KW - Chronic otitis media

KW - Levofloxacin (LVFX)

KW - MRSA

UR - http://www.scopus.com/inward/record.url?scp=0033959488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033959488&partnerID=8YFLogxK

U2 - 10.5631/jibirin.93.77

DO - 10.5631/jibirin.93.77

M3 - Article

AN - SCOPUS:0033959488

VL - 93

SP - 77

EP - 84

JO - Practica Otologica

JF - Practica Otologica

SN - 0032-6313

IS - 1

ER -

High-dose administration of levofloxacin (LVFX) in the treatment of acute exacerbation of chronic otitis media

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this